Since VEGF-inhibitor-induced hypertension can be managed in the same way as in otherwise healthy hypertensive patients, and both sunitinib and sorafenib improve PFS, the risk of TKI-induced hypertension seems to be counterbalanced by the beneficial effects of the cancer treatment. Here, VEGFA is linked to cancer.